✦ LIBER ✦

Dose optimization in drug development: role of phase IV trials

✍ Scribed by Pieter H. Joubert

Book ID: 117549543
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 298 KB
Volume: 1220
Category: Article
ISSN: 0531-5131
DOI: 10.1016/s0531-5131(01)00286-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Role of Age on Dose-Limiting Toxicit

The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials

✍ Schwandt, A.; Harris, P. J.; Hunsberger, S.; Deleporte, A.; Smith, G. L.; Vulih, 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 331 KB

Role of the investigator in phase 1 tria

Role of the investigator in phase 1 trials of anticancer drugs

✍ Nicolas Penel; Antoine Adenis; Jacques Bonneterre 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 205 KB

Role of modelling and simulation in Phas

Role of modelling and simulation in Phase I drug development

✍ Leon Aarons; Mats O. Karlsson; France Mentré; Ferdinand Rombout; Jean-Louis Stei 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 76 KB

[Ernst Schering Research Foundation Work

[Ernst Schering Research Foundation Workshop] Appropriate Dose Selection — How to Optimize Clinical Drug Development Volume 59 || The Role of PET Scanning in Determining Pharmacoselective Doses in Oncology Drug Development

✍ Venitz, J.; Sittner, W. 📂 Article 📅 2007 🏛 Springer Berlin Heidelberg 🌐 English ⚖ 221 KB

The use of cognitive tests to facilitate

The use of cognitive tests to facilitate drug and dose selection in Phase I and to optimise dosing in Phase IV

✍ Keith A Wesnes 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Recommendations for Phase IV Studies in

Recommendations for Phase IV Studies in the Development of Lipid-Lowering Drugs

✍ R.E. Gregg 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 40 KB